Alfumax ER Tablet (Extended Release)
Alfumax ER Tablet (Extended Release) is manufactured by Unimed Unihealth MFG. Ltd. Alfumax ER Tablet (Extended Release) contains 10 mg Alfuzosin Hydrochloride. It is Alpha adrenoceptor blocking drugs class drug.
Alfumax ER is a selective antagonist of post-synaptic a1 adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra. Alfumax ER relaxes the tone of the prostate smooth muscle, prostate capsule, bladder neck and proximal urethra. It competitively and selectively binds to the post synaptic a1-adrenergic receptors in the lower urinary tract. It also relaxes sympathetic nervous stimulation, reduces resting urethral pressure and inhibits urethral hypertonia-induced sympathetic nervous stimulation. As an uroselective agent, Alfumax ER preferentially binds to prostatic a1 receptors, blockage of these receptors result in reduction of BPH symptoms, improvement of urine flow and decreased potential for hypertensive events.
Alfumax ER is used for the treatment of the signs and symptoms of benign prostatic hyperplasia(BPH), lower urinary tract symptoms (LUTS) including urinary frequency, nocturia, incomplete emptying and urinary hesitancy associated with BPH.
|Brand Name:||Alfumax ER|
|Type:||Tablet (Extended Release)|
|Therapeutic Class:||Alpha adrenoceptor blocking drugs|
|Manufacturer:||Unimed Unihealth MFG. Ltd|
|Last Updated:||November 21, 2020 at 6:15 pm|
Table Of contents
Alfumax ER contains Alfuzosin Hydrochloride 10 mg. Alfumax ER Dosage:
The recommended dosage is one 10 mg Alfumax ER tablet daily to be taken immediately after the same meal each day. The tablets should not be chewed or crushed.
Alfumax ER tablet should be swallowed whole.
This formulation is generally well tolerated. However the following adverse events have been reported include abdominal pain, dyspepsia, constipation, nausea, impotence, bronchitis, sinusitis and pharyngitis.
Alfumax ER should not be given to patients with moderate or severe hepatic insufficiency. Caution should be exercised when Alfuzosin is administered in patients with severe renal insufficiency. If symptoms of angina pectoris should newly appear or worsen, Alfumax ER should be discontinued.
Alfuzosin may interact with other alpha-blockers, Atenolol, Cimetidine, Diltiazem, Ketoconazole and Ritonavir.
Pregnancy Lactation use
Alfumax ER is not indicated for use in pregnant and lactating mother.
Alfumax ER tablet is contraindicated for hypersensitivity to Alfumax ER, history of orthostatic hypotension, combination with other alpha-1 receptor blockers, hepatic insufficiency.
Efficacy of Alfumax ER has not been demonstrated in children aged 2 to 16 years. Therefore Alfumax ER is not indicated for use in the paediatric population.
Overdose of Alfumax ER should lead to hypotension; support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, then the administration of intravenous fluids should be considered. If necessary, vasopressors should then be used, and the renal function should be monitored and supported as needed.
Interaction with other Medicine
Store in a cool and dry place, protected from light